Hydroxyurea and Primary myelofibrosis - a phase IV clinical study of FDA data
Primary myelofibrosis is found among people who take Hydroxyurea, especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months.
The phase IV clinical study analyzes which people take Hydroxyurea and have Primary myelofibrosis. It is created by eHealthMe based on reports of 13,652 people who have side effects when taking Hydroxyurea from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
13,652 people reported to have side effects when taking Hydroxyurea.
Among them, 141 people (1.03%) have Primary myelofibrosis.
What is Hydroxyurea?
Hydroxyurea has active ingredients of hydroxyurea. It is often used in polycythemia vera. eHealthMe is studying from 13,923 Hydroxyurea users for its effectiveness, alternative drugs and more.
What is Primary myelofibrosis?
Primary myelofibrosis (primary disorder of the bone marrow) is found to be associated with 1,090 drugs and 769 conditions by eHealthMe.
Number of Hydroxyurea and Primary myelofibrosis reports submitted per year:
Time on Hydroxyurea when people have Primary myelofibrosis *:
Gender of people who have Primary myelofibrosis when taking Hydroxyurea*:
Age of people who have Primary myelofibrosis when taking Hydroxyurea *:
Common drugs people take besides Hydroxyurea *:
Common side effects people have besides Primary myelofibrosis *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Hydroxyurea and have Primary myelofibrosis?Check whether Primary myelofibrosis is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Primary myelofibrosis and when was it recovered:
Expand to all the drugs that have ingredients of hydroxyurea:
Alternative drugs to, pros and cons of Hydroxyurea:
- Hydroxyurea (13,923 reports)
Common Hydroxyurea side effects:
- Fatigue (feeling of tiredness): 1,423 reports
- Diarrhea: 1,237 reports
- Headache (pain in head): 981 reports
- Thrombocytopenia (decrease of platelets in blood): 892 reports
- Weakness: 794 reports
- Fever: 786 reports
- Pain: 754 reports
Browse all side effects of Hydroxyurea:a b c d e f g h i j k l m n o p q r s t u v w x y z
Primary myelofibrosis treatments and more:
- Primary myelofibrosis (35,056 reports)
COVID vaccines that are related to Primary myelofibrosis:
- Primary myelofibrosis in Moderna COVID Vaccine
- Primary myelofibrosis in Pfizer BioNTech Covid Vaccine
- Primary myelofibrosis in Johnson and Johnson Covid Vaccine
Common drugs associated with Primary myelofibrosis:
- Jakafi: 776 reports
- Aspirin: 275 reports
- Hydrea: 264 reports
- Lopurin: 171 reports
- Allopurinol: 171 reports
- Exjade: 156 reports
- Nplate: 155 reports
- Prednisone: 152 reports
- Hydroxyurea: 141 reports
- Prednisolone: 141 reports
All the drugs that are associated with Primary myelofibrosis:
- Primary myelofibrosis (1,090 drugs)
Common conditions associated with Primary myelofibrosis:
- High blood pressure: 141 reports
- Idiopathic thrombocytopenic purpura (itp): 108 reports
All the conditions that are associated with Primary myelofibrosis:
- Primary myelofibrosis (769 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on hydroxyurea (the active ingredients of Hydroxyurea) and Hydroxyurea (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Hydrodiuril and Gastric Ulcer - a second ago
- Cyclosporine and Blood Albumin Decreased - 2 seconds ago
- Coumadin and Muscle Tightness - 2 seconds ago
- Cotrim and Chronic Lymphocytic Leukaemia Transformation - 4 seconds ago
- Hydrodiuril and Joint Pain - 6 seconds ago
- Hydrodiuril and Erythema Multiforme - 6 seconds ago
- Adderall 30 and Cyst - 7 seconds ago
- Cycrin and Macrocytosis - 12 seconds ago
- Curretab and Ovarian Cancer - 19 seconds ago
- Cotrim and Chronic Lymphocytic Leukaemia - 20 seconds ago